logo
Porter County commissioners raise rates for parking garage to keep up with maintenance costs

Porter County commissioners raise rates for parking garage to keep up with maintenance costs

Chicago Tribune2 days ago

To recoup more than $600,000 in maintenance costs, Porter County is increasing the fee to park in the county garage south of the administration building during Popcorn Fest and also doubling the contract fee the city of Valparaiso pays to use the garage after business hours and on weekends.
The fee to park during the Popcorn Fest will increase from $15 to $20 for the day and Valparaiso's contract fee is being doubled from $15,000 to $30,000. Under that contract, public parking is free from 5 p.m. to 1 a.m. on weekdays and from 9 a.m. to 1 a.m. on weekends.
Last year, after a decade at $10 for the day of Popcorn Fest, the parking fee was raised to $15. At the time there had been talk of going to $20 but commissioners were uncomfortable with such a large jump all at once.
Commissioner Barb Regnitz, R-Center, asked if any conversation had been had with the city about the proposed increase. 'Whatever conversation we're going to have is going to be one-sided,' replied Board of Commissioners President Jim Biggs, R-North. 'They're not going to like it.'
Biggs said Valparaiso didn't cut the county any slack in requiring it to pay a $39,000 building permit fee for the ongoing renovations to the Porter County Jail which is within city limits. 'Love doing business with them,' he said, 'but we have our own business to take care of here.'
Porter County Facilities Director Joe Wiszowaty told the Board of Commissioners at its meeting Tuesday morning that $300,000 has already been spent on a complete overhaul of the garage and another $300,000 in maintenance is expected to be spent over the next five years.
The garage was built in 1994 and recently had a full-depth restoration in which rebar was redone and deteriorated areas of the garage deck cut out and replaced. An epoxy overlay was also put on all seams.
'It should last a hundred years, easy,' Wiszowaty said. 'We've done all the corrective steps.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NewAmsterdam Pharma to Host R&D Day on June 11, 2025

Yahoo

time33 minutes ago

  • Yahoo

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in to access your portfolio

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Yahoo

time2 hours ago

  • Yahoo

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

SAN DIEGO, June 05, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Business Wire

time2 hours ago

  • Business Wire

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store